

Approval for German Medical Device in China

Successful cooperation of GILUPI GmbH with its Chinese partner
Viroad

The GILUPI CellCollector® - the first medical device for in vivo CTC isolation, manufactured by GILUPI - has been approved by the Chinese registrations agency (China Food and Drug Administration - CFDA) in June. As a result, the Potsdam-based company gains access to one of the most significant geographical markets worldwide. This milestone was reached in close cooperation with GILUPI's strategic partner, Hebei Viroad Biotechnology Co. Ltd. (Viroad). Besides its role as strategic partner, Viroad is also the largest investor and shareholder of GILUPI.


Alexander Herrmann, Managing Director of GILUPI GmbH commented: "Viroad is an excellent partner and we achieved this important approval based on their outstanding knowledge of the Chinese market and their regulatory expertise. Together with Viroad, we can realize a rapid market access in China and expect a significant sales growth within the next years."

The importance of the strategic partnership with Viroad to GILUPI is also pointed out by Brandenburg's Economic State Secretary Hendrik Fischer and the CEO of Brandenburg Invest (WFBB), Sebastian Saule, during their current delegation visit to China. Today, they visit Ms. Baozhi Xu the CEO of Hebei Viroad in Shijiazhuang, the capital of Brandenburg's partner province Hebei. State Secretary Fischer explained: "The economic relations with China are very important for the German county Brandenburg. We are pleased that a Brandenburg company is generating attention on the Chinese healthcare market". WFBB CEO Saule says: "This is a new quality on external economic relations with China and at the same time strengthens the healthcare location Brandenburg. This is of course a wonderful success of the joint efforts in China and Brandenburg, supporting the development of GILUPI."

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-



based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com